Compounds of general formula:

##STR00001##

wherein R.sup.0A and R.sup.0B are independently selected from hydrogen and pharmaceutically acceptable cations; and R.sup.A and R.sup.B are identical and selected from amide, carbamate, sulphonamide, azido, cyano and halide. Also, a pharmaceutical composition including one of the compounds. The composition may also include another active ingredient, especially an antineoplastic agent. Further a compound or a composition for use as a medicament, especially a compound or a composition for use in the treatment of a proliferative disease such as for example cancer.

A bimetal oxysulfide solid-solution catalyst is provided. The bimetal oxysulfide solid-solution catalyst is represented by formula (1):
M.sup.(1).sub.xM.sup.(2).sub.yO.sub.zS.sub.(1), wherein in formula (1), M.sup.(1) includes Copper (Cu) and M.sup.(2) includes monovalent Silver (Ag), divalent Zinc (Zn), Manganese (Mn), Nickel (Ni), Cobalt (Co), and Tin (Sn.sup.II), trivalent Indium (In), Cerium (Ce), Antimony (Sb), and Gallium (Ga), tetravalent Tin (Sn.sup.IV), or pentavalent Molybdenum (Mo), 0<y<0.3, 0.7<x<1.0, 0<z<0.5, and 0.5<<1.0. In addition, a manufacturing method of the bimetal oxysulfide solid-solution catalyst and applications of the bimetal oxysulfide solid-solution catalyst are also provided.

The present disclosure is directed to salts and free bases of Compounds of Formula (I), including crystalline, semi-crystalline, amorphous, and polymorph forms thereof, and processes for their preparation.

The present disclosure is directed to salts and free bases of Compounds of Formula (I), including crystalline, semi-crystalline, amorphous, and polymorph forms thereof, and processes for their preparation.